HR and breast cancer: Another AKT inhibitor, capivasertib, was investigated in the phase III trial CAPItello-291 (NCT04305496), which included patients with HR+/HER2− advanced BC who had a relapse or disease progression during or after treatment with an AI, with (69.1%) or without previous CDK4/6i therapy [231].